Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 151

    1.

    Has tamoxifen had its day?

    Baum M.

    Breast Cancer Res. 2002;4(6):213-7. Epub 2002 Aug 27.

    PMID:
    12473165
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

    Aapro MS, Forbes JF.

    Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

    PMID:
    14535530
    [PubMed - indexed for MEDLINE]
    3.

    Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.

    Lancet. 2005 Jan 1-7;365(9453):60-2.

    PMID:
    15639680
    [PubMed - indexed for MEDLINE]
    4.

    Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

    Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG.

    Lancet. 2005 Aug 6-12;366(9484):455-62.

    PMID:
    16084253
    [PubMed - indexed for MEDLINE]
    7.

    Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

    Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M.

    Lancet Oncol. 2008 Jan;9(1):45-53.

    PMID:
    18083636
    [PubMed - indexed for MEDLINE]
    8.

    Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

    Dunn C, Keam SJ.

    Pharmacoeconomics. 2006;24(5):495-517. Review.

    PMID:
    16706574
    [PubMed - indexed for MEDLINE]
    9.

    Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.

    Bell R, Lewis J.

    Curr Med Res Opin. 2007 May;23(5):1045-51.

    PMID:
    17519070
    [PubMed - indexed for MEDLINE]
    10.

    Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

    J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

    PMID:
    17200148
    [PubMed - indexed for MEDLINE]
    11.

    Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

    Buzdar A.

    Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

    PMID:
    12756078
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Focus on anastrozole and breast cancer.

    Mokbel K.

    Curr Med Res Opin. 2003;19(8):683-8. Review.

    PMID:
    14687437
    [PubMed - indexed for MEDLINE]
    13.

    Anastrozole.

    Cuzick J.

    Drugs Today (Barc). 2005 Apr;41(4):227-39. Review.

    PMID:
    16034487
    [PubMed - indexed for MEDLINE]
    14.

    Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

    Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

    J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

    PMID:
    18073378
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

    Jahanzeb M.

    Clin Ther. 2007 Aug;29(8):1535-47. Review.

    PMID:
    17919537
    [PubMed - indexed for MEDLINE]
    16.

    Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.

    Munster PN, Horton J.

    Cancer Control. 2001 Nov-Dec;8(6):478-9. No abstract available.

    PMID:
    11807416
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

    Carlson RW, Henderson IC.

    Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

    PMID:
    14535531
    [PubMed - indexed for MEDLINE]
    18.

    Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.

    Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R.

    Lancet Oncol. 2006 Dec;7(12):991-6. Erratum in: Lancet Oncol. 2007 Jan;8(1):6.

    PMID:
    17138220
    [PubMed - indexed for MEDLINE]
    19.

    Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.

    Mouridsen HT, Robert NJ.

    MedGenMed. 2005 Aug 24;7(3):20. Review.

    PMID:
    16369246
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

    Carpenter R.

    Eur J Surg Oncol. 2008 Jul;34(7):746-55. Epub 2008 Mar 4. Review.

    PMID:
    18296017
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk